I

IFRX: InflaRx NV

Stock

About

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Website
www.inflarx.de
Year Founded
2007
Employees
66
Sector
Health Care
HQ Location
Jena, undefined

Current Value

$1.10

1 Year Return

$0.45
-29.03%
Created with Highcharts 11.4.829 Apr27 May24 Jun22 Jul19 Aug16 Sep14 Oct11 Nov9 Dec6 Jan3 Feb3 Mar31 Mar$0.5$1$1.5$2$2.5$3

Key Details

Market Cap

$70.49M

P/E Ratio

-1

1Y Stock Return

-32.69%

1Y Revenue Growth

178.84%

Dividend Yield

0.00%

Price to Book

0.8

Strategies that include IFRX

Create your own
strategy with

IFRX
Three dimensional double logo

Stock's related to IFRX

The stocks that are correlated to IFRX - InflaRx NV are FRT, FWONK, PDM, ENB, CRNX

Name
Correlation
Market Cap
Return % (1 Year)
Div Yield %
F
FRTFederal Realty Investment Trust
33.31%$7.95B-6.71%4.85%
F
FWONKLiberty Media Corp.
30.00%$21.61B+28.94%0.00%
P
PDMPiedmont Office Realty Trust, Inc.
28.51%$860.90M+6.30%7.44%
E
ENBEnbridge, Inc.
28.19%$98.80B+27.22%6.01%
C
CRNXCrinetics Pharmaceuticals, Inc.
27.96%$2.69B-38.11%0.00%
I
INFAInformatica, Inc. (California)
27.65%$5.13B-52.45%0.00%
I
IONQIonQ, Inc.
27.45%$5.18B+154.93%0.00%
A
AKRAcadia Realty Trust
27.40%$2.33B+19.37%4.00%
D
DEIDouglas Emmett, Inc.
27.38%$2.44B+11.63%5.26%
F
FWONALiberty Media Corp.
27.32%$19.45B+30.16%0.00%
B
BNTBrookfield Wealth Solutions Ltd.
27.01%$10.14B+25.87%0.00%
O
OMEROmeros Corp.
26.92%$427.35M+135.90%0.00%
M
MCOMoody's Corp.
26.89%$79.58B+12.98%0.82%
K
KIMKimco Realty Corp.
26.73%$13.64B+7.90%5.07%
R
RCUSArcus Biosciences, Inc.
26.57%$758.88M-58.48%0.00%
U
UEUrban Edge Properties
26.04%$2.26B+8.61%3.98%
B
BNBrookfield Corp.
25.93%$75.46B+25.56%0.69%
J
JBGSJBG SMITH Properties
25.72%$1.28B+0.26%4.55%
G
GPCRStructure Therapeutics, Inc.
25.67%$935.49M-58.45%0.00%
D
DNLIDenali Therapeutics, Inc.
25.64%$1.86B-32.65%0.00%

ETF's related to IFRX

The ETFs that are correlated to IFRX - InflaRx NV are XBI, IBB, GNOM, INDY, BTC

Name
Correlation
AUM
Expense Ratio
X
XBISPDR Biotech ETF
31.69%$5.06B0.35%
I
IBBiShares Biotechnology ETF
30.31%$5.70B0.45%
G
GNOMGlobal X Genomics & Biotechnology ETF
28.15%$48.48M0.5%
I
INDYiShares India 50 ETF
27.69%$646.31M0.89%
B
BTCCommon units of fractional undivided beneficial interest
26.78%$3.28B0.15%
F
FLINFranklin FTSE India ETF
26.62%$1.78B0.19%
P
PBEInvesco Biotechnology & Genome ETF
26.49%$229.13M0.58%
B
BBHVanEck Biotech ETF
26.38%$362.92M0.35%
E
EPIWisdomTree India Earnings Fund
26.25%$3.06B0.85%
U
UOCTInnovator U.S. Equity Ultra Buffer ETF October
26.08%$201.49M0.79%
B
BUFDTraded Fund VIII FT Vest Laddered Deep Buffer ETF
26.00%$1.24B0.95%
P
PDECInnovator U.S. Equity Power Buffer ETF December
25.95%$1.01B0.79%
B
BUFFInnovator Laddered Allocation Power Buffer ETF
25.90%$577.20M0.89%
U
USEPInnovator U.S. Equity Ultra Buffer ETF September
25.75%$128.92M0.79%
I
IWCiShares Micro Cap ETF
25.67%$809.63M0.6%
P
PINInvesco India ETF
25.64%$220.64M0.78%
R
RYLDGlobal X Russell 2000 Covered Call ETF
25.62%$1.39B0.6%
I
INDAiShares MSCI India ETF
25.59%$8.95B0.62%
F
FTHITraded Fund VI First Trust BuyWrite Income ETF
25.59%$1.28B0.75%
U
UDECInnovator U.S. Equity Ultra Buffer ETF December
25.46%$329.48M0.79%

News

Finnhub

Received European Commission approval for GOHIBIC® for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial...

Finnhub

JENA, Germany, March 07, 2025 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple...

Finnhub

JENA, Germany, Feb. 28, 2025 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted...

Finnhub

JENA, Germany, Feb. 25, 2025 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will...

Finnhub

JENA, Germany, Feb. 18, 2025 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its...

Finnhub

JENA, Germany, Jan. 23, 2025 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in...

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Zero expense ratio
index investing

Company

Resources

Popular ETFs

ETF Comparisons

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.

0% Expense Ratios with TLH

We offer over 50 indexes with zero expense ratios.

Registration will take about 10 seconds